Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00290472 · OUTCOME

Overall Survival

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · Source last updated 2014-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Month
Interval / dispersion
95% Confidence Interval
Time frame
Up to 6 years

What was measured

The overall survival was evaluated using the Kaplan-Meier estimator.

Groups in this outcome

Aggressive B-cell Lymphoma

Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Aggressive B-cell lymphoma group was defined as patients with histologic subtypes included diffuse large B-cell lymphoma and transformed follicular lymphoma.

Follicular Lymphoma

Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Follicular lymphoma group was defined as patients with histologic subtypes included follicular lymphoma.

Chronic Lymphocytic Leukemia

Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Chronic lymphocytic leukemia group was defined as patients with histologic subtypes included chronic lymphocytic leukemia, small lymphocytic lymphoma, and other indolent lymphomas.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Aggressive B-cell Lymphoma32
Follicular Lymphoma39
Chronic Lymphocytic Leukemia18

Reported measurements

Source class 1
Values in Month · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Aggressive B-cell Lymphoma7.3Not reported4.318.1Not reported
Follicular LymphomaNANot reportedNANAThe median Overall Survival and the associated 95% CI was not reached.
Chronic Lymphocytic Leukemia31.5Not reported9.5NAThe upper limit of the 95% CI interval was undetermined due to the heavy censoring.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.3
        upper Limit
        18.1
        value
        7.3
      2. comment
        The median Overall Survival and the associated 95% CI was not reached.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      3. comment
        The upper limit of the 95% CI interval was undetermined due to the heavy censoring.
        group Id
        OG002
        lower Limit
        9.5
        upper Limit
        NA
        value
        31.5
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    2. group Id
      OG001
      value
      39
    3. group Id
      OG002
      value
      18
    units
    Participants
description
The overall survival was evaluated using the Kaplan-Meier estimator.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Aggressive B-cell lymphoma group was defined as patients with histologic subtypes included diffuse large B-cell lymphoma and transformed follicular lymphoma.
    id
    OG000
    title
    Aggressive B-cell Lymphoma
  2. description
    Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Follicular lymphoma group was defined as patients with histologic subtypes included follicular lymphoma.
    id
    OG001
    title
    Follicular Lymphoma
  3. description
    Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Chronic lymphocytic leukemia group was defined as patients with histologic subtypes included chronic lymphocytic leukemia, small lymphocytic lymphoma, and other indolent lymphomas.
    id
    OG002
    title
    Chronic Lymphocytic Leukemia
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 6 years
title
Overall Survival
type
PRIMARY
unit Of Measure
Month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice